When you are raising €1M to €10M+, a pitch deck that is "good enough" is a death sentence. Investors at this level are not looking for a well-designed story. They are running a clinical evaluation of your business logic, your market command, and your team's capacity to execute under pressure.
Most founders lose not because their company is weak — but because their pitch deck has a silent killer buried inside it. A single broken vital sign that triggers the polite pass. The Pitch Vitals Check is the mandatory diagnostic to find it — before it finds your round.
At the Seed to Series A level, investors do not tell you what killed your pitch. They schedule a follow-up that never comes. They introduce you to someone who "might be a better fit." They say your deck is strong but the timing is off.
They don't say: "Your narrative architecture collapsed on slide three." Or: "Your unit economics triggered a red flag we don't discuss with founders." They simply move on.
The result: you iterate on the wrong things, burn warm introductions, and approach the next meeting with the same silent killer in your deck.
None of this is solved by redesigning slides. It is solved by a rigorous, investor-grade diagnostic that identifies exactly which vital sign is failing — and why.
Most founders treat their pitch deck like a design project. I treat it like a high-stakes clinical diagnosis.
When you are raising €1M to €10M+, "good enough" is a death sentence. I don't "review" your slides. I run your entire business case through my proprietary 42-Point Surgical Scan — a rigorous, investor-grade audit designed to identify the "silent killers" in your story before they reach the partner meeting.
Instead of guessing why you're receiving polite passes, you will receive a clinical breakdown of the 7 Vital Organs of your pitch — the exact dimensions on which institutional investors evaluate whether your business logic is fundable at this level.
An objective, VC-grade rating of your deck's strategic strength across all 7 Vital Organs, calibrated to Seed-to-Series A benchmark standards.
A color-coded clinical breakdown identifying the exact status of each vital organ: what is performing, what is deteriorating, and what is actively killing your round.
A surgical roadmap of the highest-impact changes required to secure your round — ranked by investor impact, not by the ease of implementation. This is your operating plan.
The process is designed to be frictionless for the founder. No calls. No scheduling overhead. Your time is for raising, not for coordination.
Complete payment via Stripe. You will immediately receive a concise intake form requesting your current deck, your raise target, your round stage, and the investor feedback you have received to date. This pre-operative context is not optional — it is how the diagnostic is calibrated to your specific business architecture.
Your deck is subjected to a rigorous, investor-grade audit across the 7 Vital Organs. I apply the same scrutiny a seasoned Series A partner would bring to an initial deck review — with the added precision of knowing exactly which checkpoints most founders fail at this level, and why.
Within 5 business days, you receive your written report: the Investor Readiness Score, the Triage Map, and the Priority Fix roadmap. Clinical, specific, and actionable. No vague observations. No generic advice. A precise diagnosis of your deck's condition.
The report closes with a direct clinical assessment: whether you can execute the required fixes independently, or whether the findings indicate that Full Pitch Surgery is the appropriate intervention. If surgery is recommended, your €500 diagnostic fee applies in full toward the procedure.
I am not a pitch deck designer. I am not a brand strategist. My background is in high-stakes executive decision-making at the institutional level — in Supply Chain at companies like Canon Europe and Kyocera Document Solutions, where I spent over two decades building and defending business cases that had to survive the most rigorous financial and strategic scrutiny imaginable.
I know precisely what it takes to walk into a room with powerful, skeptical decision-makers and command their conviction. I know how they evaluate logic. I know what triggers doubt before a word is spoken. And I know the specific moment — often invisible to the presenter — when a business case loses the room.
After leaving corporate leadership, I spent considerable time conducting a systematic study of what separates funded pitches from failed ones at the Seed to Series A level: analyzing hundreds of decks, dissecting the investment logic of leading VC firms, and building the diagnostic framework that became the 42-Point Surgical Scan.
I do not operate at consultancy distance. I do not offer workshops. I do not sell frameworks that you implement yourself. I diagnose your deck with the precision of a specialist who has spent a career reading between the lines of high-stakes business cases — and I tell you exactly what is failing and why.
At the Seed to Series A level, the founders who close rounds are not always those with the strongest businesses. They are the founders whose pitch communicates Strategic Command, Unshakable Logic, and Investor-Grade Precision from the first slide. That command does not come from better design. It comes from a diagnostic that eliminates every silent killer before you walk into the room.